Patients with nonalcoholic fatty liver disease display increased serum resistin levels and decreased adiponectin levels

European Journal of Gastroenterology and Hepatology

Volumn 21, Issue 6, 2009, Pages 662-666

  Jiang, Ling Jing ^a   Li, J Lin ^a   Hong, Xiao Fei ^b   Li, You Ming ^a   Zhang, Bing Ling ^a,c  

^a ZHEJIANG UNIVERSITY   (China)

^b Central Hospital   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Adiponectin; Nonalcoholic fatty liver disease; Obesity; Resistin

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; FAT; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; RESISTIN; TRIACYLGLYCEROL;

ABDOMINAL FAT; ABDOMINAL WALL; ABNORMAL SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; BODY FAT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROL GROUP; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIP; HUMAN; HYPERRESISTINEMIA; HYPOADIPONECTINEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPONECTIN; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTHROPOMETRY; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY FAT DISTRIBUTION; BODY MASS INDEX; CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; HUMANS; LIPIDS; MALE; MIDDLE AGED; RESISTIN; WAIST CIRCUMFERENCE; YOUNG ADULT;

EID: 67649643618     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328317f4b5     Document Type: Article

References (32)

1. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis 1999; 17:80-89.
2. Kojima S, Watanabe N, Numata M, Ogawa T, Matsuzaki S. Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background. J Gastroenterol 2003; 38:954-961.
3. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wrighr CM, et al. The hormone resistin links obesity and diabetes. Nature 2001; 409: 307-312.
4. Louthan MV, Barve S, McClain CJ, Joshi-Barve S. Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. J Pediatr 2005; 147:835-838.
5. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizana H, Kishida K, et al. PPAR ligands increase expression and plasma concentration of adiponectin, an adipose derived protein. Diabetes 2001; 50:2094-2099.
6. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vase Biol 2000; 20: 1595-1599.
7. Otto C, Otto B, Frost RJ, Vogeser M, Pfeiffer AF, Spranger J, Parhofer KG. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. Acta Diabetol 2007; 44:65-68.
8. Otto C, Otto B, Goke B, Pfeiffer AF, Lehrke M, Vogeser M, et al. Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels. J Endocrinol Invest 2006; 29:231-236.
9. Wasim H, Al-Daghri NM, Chetty R, McTernan PG, Barnett AH, Kumar S. Relationship of serum adiponectin and resistin to glucose intolerance and fat topography in South-Asians. Cardiovasc Diabetol 2006; 5:10.
10. Chinese Liver Disease Association. Diagnostic criteria of nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi 2003; 11:71.
11. Sanage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV, et al. Resistin/Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 2001; 50:2199-2202.
12. Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest 2003; 111:225-230.
13. Pagano C, Soardo G, Pilon C, Milocco C, Basan L, Milan G, et al. Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. J Clin Endocrinol Metab 2006; 91:1081-1086.
14. Perseghin G, Lattuada G, De Cobelli F, Ntali G, Esposito A, Burska A, et al. Serum resistin and hepatic fat content in nondiabetic individuals. J Clin Endocrinol Metab 2006; 91:5122-5125.
15. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non-alcoholic fatty liver disease in obese children. EndocrJ 2005; 52:519-524.
16. Lu HL, Wang HW, Wen Y, Zhang MX, Lin HH. Roles of adipocyte derived hormone adiponectin and resistin in insulin resistance of type 2 diabetes. World J Gastroenterol 2006; 12:1747-1751.
17. Way JM, Gorgiin CZ, Tong Q, Uysal KT, Brown KK, Harrington WW, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 2001; 276:25651-25653.
18. Nagaev I, Smith U. Insulin resistance and type 2 diabetes are not related to resistin expression in human fat cells or skeletal muscle. Biochem Biophys Res Commun 2001; 285:561-564.
19. Yoon D, Lee SH, Park HS, Lee JH, Park JS, Cho KH, Kim SM. Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci 2005; 20:421-426.
20. Aygun C, Senturk O, Hulagu S, Uraz S, Celebi A, Konduk T, et al. Serum levels of hepatoprotective peptide adiponectin in non-alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006; 18:175-180.
21. Targher G, Bertolini L, Rodella S, Zoppini G, Scala L, Zenari L, et al. Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease. Clin Endocrinol (Oxf) 2006; 64:679-683.
22. Wong VW, Hui AY, Tsang SW, Chan Jl-Tse AM, Chan KF, et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006; 4:1154-1161.
23. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2008; 27:412-421.
24. Saito K, Tobe T, Yoda M, Nakano Y, Choi-Miura NH, Tomita M. Regulation of gelatin-binding protein 28 (GBP28) gene expression by C/EBP. Biol Pharm Bull 1999; 22:1158-1162.
25. Tang JF, Yang Y, Wang QD, Li JP, Gu WQ, Hong J, et al. Relationship between serum adiponectin concentration and adiposity. Zhonghua Neifenmi Daixie Za Zhi 2003; 19:166-169.
26. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistence and hyperinsulinemia. J Clin Endocrinol Metab 2001; 86:1930-1935.
27. Kubota N, Terauchi Y, Yamauchi T, Kubota T, Moroi M, Matsui J, et al. Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 2002; 227:25863-25866.
28. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC, Matsuzawa Y. Circulation concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes 2001; 50:1126-1133.
29. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001; 7:941-946.
30. Lopez-Bermejo A, Botas P, Funahashi T, Delgado E, Kihara S, Ricart W, Fernandez-Real JM. Adiponectin, hepatocellular dysfunction and insulin sensitivity. Clin Endocrinol 2004; 60:256-263.
31. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver disease in mice. J Clin Invest 2003; 112:91-100.
32. Matsumoto H, Tamura S, Kamada Y, Kiso S, Fukushima J, Wada A, ef al. Adiponectin deficiency exacerbates lipopolysaccharide/D-galactosamine- induced liver injury in mice. World J Gastroenterol 2006; 12:3352-3358.